Rules would prevent certain complex medicines from being reclassified due to inactive ingredients.
This bill would change how the government classifies certain complex medicines, called biologics. It would stop the Food and Drug Administration (FDA) from reclassifying a biologic as a "biological product" just because it contains a protein that doesn't have any medical effect. This change is intended to help patients keep access to these medicines under their current rules and potentially prevent price changes or market issues.
Today, the law defines "biological product" but doesn't explicitly stop the FDA from classifying a biologic as such just because it has a clinically inactive protein. This bill would change that by explicitly prohibiting the FDA from treating a biologic as a biological product solely based on the presence of a protein that does not have a medical effect.
HR 8630 · 119th Congress · April 30, 2026 · AI Summary by gemini-2.5-flash · 8/10
Sign in to see your representatives' phone numbers